Table 2 |
||||||
|
Serum uric acid lab results |
||||||
|
Patient Characteristics |
No CKD (N = 2,393) |
Stage 2 CKD (N = 1,032) |
Stage 3 CKD (N = 357) |
Stage 4 CKD (N = 147) |
p-value |
|
|
|
||||||
|
Number of subjects with a lab result |
N |
1,542 |
645 |
220 |
73 |
|
|
|
||||||
|
% |
64.44 |
62.5 |
61.62 |
49.66 |
0.0033 |
|
|
|
||||||
|
Value of last sUA test during follow-up period: all subjects |
mean |
6.86 |
7.09 |
7.56 |
7.72 |
< .0001 |
|
SD |
1.9 |
1.9 |
2.1 |
2.11 |
||
|
|
||||||
|
Achieved goal of < 6 mg/dL based on last test during follow-up: all subjects |
n |
526 |
191 |
50 |
16 |
|
|
% |
34.11 |
29.61 |
22.73 |
21.92 |
0.0008 |
|
|
|
||||||
|
Value of last sUA test during follow-up period: allopurinol users |
mean |
6.75 |
6.93 |
7.46 |
7.56 |
< .0001 |
|
SD |
1.91 |
1.85 |
2.11 |
2.05 |
||
|
|
||||||
|
Achieved goal of < 6 mg/dL based on last test during follow-up: allopurinol users |
n |
448 |
172 |
49 |
16 |
|
|
% |
25.64 |
23.31 |
20.16 |
18.82 |
0.1247 |
|
|
|
||||||
|
SD = standard deviation. |
||||||
|
Fuldeore et al. BMC Nephrology 2011 12:36 doi:10.1186/1471-2369-12-36 |
||||||
